DE10224108A1 - 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung - Google Patents

1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung Download PDF

Info

Publication number
DE10224108A1
DE10224108A1 DE10224108A DE10224108A DE10224108A1 DE 10224108 A1 DE10224108 A1 DE 10224108A1 DE 10224108 A DE10224108 A DE 10224108A DE 10224108 A DE10224108 A DE 10224108A DE 10224108 A1 DE10224108 A1 DE 10224108A1
Authority
DE
Germany
Prior art keywords
dimethylamino
methoxyphenyl
weight
methylpentan
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10224108A
Other languages
German (de)
English (en)
Inventor
Johannes Dr. Bartholomäus
Iris Dr. Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to DE10224108A priority Critical patent/DE10224108A1/de
Priority to PT03732464T priority patent/PT1507519E/pt
Priority to ES03732464T priority patent/ES2263976T3/es
Priority to CA2488220A priority patent/CA2488220C/en
Priority to EP03732464A priority patent/EP1507519B1/de
Priority to PCT/EP2003/005488 priority patent/WO2003099267A1/de
Priority to DK03732464T priority patent/DK1507519T3/da
Priority to DE50303372T priority patent/DE50303372D1/de
Priority to JP2004506791A priority patent/JP5459818B2/ja
Priority to AU2003238397A priority patent/AU2003238397A1/en
Priority to SI200330356T priority patent/SI1507519T1/sl
Priority to PL374186A priority patent/PL218397B1/pl
Priority to AT03732464T priority patent/ATE326218T1/de
Priority to MYPI20031965A priority patent/MY134311A/en
Priority to PE2003000521A priority patent/PE20040529A1/es
Priority to ARP030101884A priority patent/AR039900A1/es
Publication of DE10224108A1 publication Critical patent/DE10224108A1/de
Priority to US10/998,159 priority patent/US7410965B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE10224108A 2002-05-29 2002-05-29 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung Withdrawn DE10224108A1 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE10224108A DE10224108A1 (de) 2002-05-29 2002-05-29 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung
AU2003238397A AU2003238397A1 (en) 2002-05-29 2003-05-26 Medicament with delayed release of the active substance, containing 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
SI200330356T SI1507519T1 (sl) 2002-05-29 2003-05-26 Zdravilo, ki vsebuje 1-dimetilamino-3-(3-metoksi-fenil)-2-metil-pentan-3-ol, z zadrzevanim sproscanjem ucinkovine
CA2488220A CA2488220C (en) 2002-05-29 2003-05-26 Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol
EP03732464A EP1507519B1 (de) 2002-05-29 2003-05-26 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
PCT/EP2003/005488 WO2003099267A1 (de) 2002-05-29 2003-05-26 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
DK03732464T DK1507519T3 (da) 2002-05-29 2003-05-26 Lægemiddel med forsinket frigivelse af det aktive middel 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methylpentan-3-ol
DE50303372T DE50303372D1 (de) 2002-05-29 2003-05-26 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
JP2004506791A JP5459818B2 (ja) 2002-05-29 2003-05-26 １−ジメチルアミノ−３−（３−メトキシ−フェニル）−２−メチル−ペンタン−３−オールを含有する、有効物質徐放性医薬
PT03732464T PT1507519E (pt) 2002-05-29 2003-05-26 Medicamento com libertacao retardada da substancia activa, contendo 1-dimetilamino-3-(3-metoxifenil)-2-metilpentan-3-ol
ES03732464T ES2263976T3 (es) 2002-05-29 2003-05-26 Medicamento de liberacion retardada del principio activo que contiene 1-dimetilamino-3-(3-metoxifenil)-2-metil-3-pentanol.
PL374186A PL218397B1 (pl) 2002-05-29 2003-05-26 Preparat farmaceutyczny o przedłużonym uwalnianiu, który w matrycy o przedłużonym uwalnianiu substancji czynnej, zawiera 1-dimetyloamino-3- (3-metoksyfenylo)-2- metylopentan-3-ol, oraz jego zastosowanie
AT03732464T ATE326218T1 (de) 2002-05-29 2003-05-26 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl- pentan-3-ol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
MYPI20031965A MY134311A (en) 2002-05-29 2003-05-28 Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol
PE2003000521A PE20040529A1 (es) 2002-05-29 2003-05-29 Medicamentos que contienen 1-demetilamino-3(3-metoxi-fenil)-2-metil-pentan-3-ol con liberacion retardada del compuesto activo
ARP030101884A AR039900A1 (es) 2002-05-29 2003-05-29 Medicamentos que contienen 1-dimetilamino-3-(3-metoxi-fenil)-2-metil-pentan-3-ol con liberacion retardada del compuesto activo
US10/998,159 US7410965B2 (en) 2002-05-29 2004-11-29 Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10224108A DE10224108A1 (de) 2002-05-29 2002-05-29 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
DE10224108A1 true DE10224108A1 (de) 2004-01-29

Family

ID=29557413

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10224108A Withdrawn DE10224108A1 (de) 2002-05-29 2002-05-29 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung
DE50303372T Expired - Lifetime DE50303372D1 (de) 2002-05-29 2003-05-26 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50303372T Expired - Lifetime DE50303372D1 (de) 2002-05-29 2003-05-26 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung

Country Status (14)

Country Link
EP (1) EP1507519B1 (enExample)
JP (1) JP5459818B2 (enExample)
AR (1) AR039900A1 (enExample)
AT (1) ATE326218T1 (enExample)
AU (1) AU2003238397A1 (enExample)
CA (1) CA2488220C (enExample)
DE (2) DE10224108A1 (enExample)
DK (1) DK1507519T3 (enExample)
ES (1) ES2263976T3 (enExample)
MY (1) MY134311A (enExample)
PE (1) PE20040529A1 (enExample)
PL (1) PL218397B1 (enExample)
PT (1) PT1507519E (enExample)
WO (1) WO2003099267A1 (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3309516A1 (de) * 1982-03-26 1983-12-01 Forest Laboratories Inc., 10022 New York, N.Y. Verfahren zur herstellung therapeutischer praeparate mit anhaltender freisetzung auf der basis von hydroxypropylmethylzellulose mit hohem molekulargewicht
JPH06172161A (ja) * 1992-12-10 1994-06-21 Shin Etsu Chem Co Ltd 徐放性錠剤
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
EP0693475B1 (de) * 1994-07-23 1998-02-11 Grünenthal GmbH 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DE10059412A1 (de) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
DE10146275A1 (de) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3309516A1 (de) * 1982-03-26 1983-12-01 Forest Laboratories Inc., 10022 New York, N.Y. Verfahren zur herstellung therapeutischer praeparate mit anhaltender freisetzung auf der basis von hydroxypropylmethylzellulose mit hohem molekulargewicht
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JPH06172161A (ja) * 1992-12-10 1994-06-21 Shin Etsu Chem Co Ltd 徐放性錠剤
EP0693475B1 (de) * 1994-07-23 1998-02-11 Grünenthal GmbH 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DE10059412A1 (de) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OHMORI,S,MAKINO,T.:Sustained-release phenylpropanolamine hydrochloride bilayer caplets containing the hydroxypropylmethylcellulose 2208 matrix.I. Formulation and dissolution characteristics.In:Chem. Pharm. Bull., Tokyo,2000 May,Vol.48,S.673-677 *
OHMORI,S,MAKINO,T.:Sustained-release phenylpropanolamine hydrochloride bilayer caplets containing the hydroxypropylmethylcellulose 2208 matrix.I. Formulation and dissolution characteristics.In:Chem. Pharm. Bull., Tokyo,2000 May,Vol.48,S.673-677;

Also Published As

Publication number Publication date
DE50303372D1 (de) 2006-06-22
EP1507519A1 (de) 2005-02-23
CA2488220A1 (en) 2003-12-04
JP5459818B2 (ja) 2014-04-02
DK1507519T3 (da) 2006-08-28
AR039900A1 (es) 2005-03-09
ATE326218T1 (de) 2006-06-15
WO2003099267A1 (de) 2003-12-04
PT1507519E (pt) 2006-08-31
PE20040529A1 (es) 2004-08-24
CA2488220C (en) 2011-02-01
EP1507519B1 (de) 2006-05-17
JP2005534640A (ja) 2005-11-17
AU2003238397A1 (en) 2003-12-12
MY134311A (en) 2007-12-31
PL218397B1 (pl) 2014-11-28
PL374186A1 (en) 2005-10-03
ES2263976T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
EP1439829B1 (de) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
DE4329794C2 (de) Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
DE60021749T2 (de) Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
EP0917463B1 (de) Tramadol multiple unit formulierungen
DE60221691T2 (de) Tamsulosin tabletten ohne nahrungsmitteleffekt
WO2010043408A2 (de) Mikroverkapseltes fesoterodin
DE602004006443T2 (de) Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung
EP2453880B1 (de) Trennschichten für pharmazeutische zubereitungen zur verhinderung von wechselwirkungen zwischen arzneistoffen und pharmazeutisch-technologischen hilfsstoffen
WO2005009329A2 (de) 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
DE60308828T2 (de) Orale pharmazeutische Zusammensetzung mit verzögerter Freisetzung
EP1928441B1 (de) Retardformulierung von 3-(2-dimethylaminomethyl-cyclohexyl)-phenol
EP1507519B1 (de) 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
US7410965B2 (en) Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
DE102013009114A1 (de) Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
DE10152469A1 (de) 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE10248309A1 (de) 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung
WO2009135623A1 (de) Galanthaminhaltiges arzneimittel mit kontrollierter freisetzung
DE19845278A1 (de) Oral applizierbare Losigamon Retardtabletten
DE102011115690A1 (de) Quetiapin enthaltende Formulierungen
DE10224556A1 (de) 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen
DE20321237U1 (de) Pharmazeutische Zusammensetzung, enthaltend Oxcarbazepin mit kontrollierter Wirkstofffreisetzung

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8139 Disposal/non-payment of the annual fee